Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

United Therapeutics (UTHR) Gets FDA Backing On Pulmonary Pipeline As Fair Value Stays In Focus

14 October 2026 · By · Wire by Fusion42

Published

14 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 15 October 2026 · Fusion42 review

United Therapeutics has gained FDA acceptance for a new drug application for ralinepag targeting pulmonary arterial hypertension, and a supplemental filing for nebulized treprostinil in idiopathic pulmonary fibrosis, supporting its advanced pulmonary pipeline.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA’s nod accelerates your path to market in pulmonary arterial hypertension and fibrosis drugs, making this a moment to assess valuation versus timing for market entry in biotech.

◆ Coverage

1 source · 14 Oct 2026

◆ Related on Wire

◆ Topics

Biotechpulmonary-diseaseFDAdrug-approvalbiotechclinical-pipeline